Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AbsEn.i » - entrée « interleukin »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
interleukein < interleukin < interleukine  Facettes :

List of bibliographic references indexed by interleukin

Number of relevant bibliographic references: 1135.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000016 (2020) M. SilbersteinVitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
000020 (2020) Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis]Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.
000031 (2020) Jerome Razanamahery [France] ; Sebastien Humbert [France] ; Helder Gil [France] ; Kevin Bouiller [France] ; Nadine Magy-Bertrand [France]Tropheryma Whipplei infection mimicking giant cell arteritis flare in a patient treated with interleukin-6 receptor blocker tocilizumab.
000048 (2020) Hazan Karadeniz [Turquie] ; Asl Han Avano Lu Güler [Turquie] ; Nuh Atas [Turquie] ; Hasan Sat [Turquie] ; Reyhan Bilici Salman [Turquie] ; Hakan Babaoglu [Turquie] ; Abdurrahman Tufan [Turquie]Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review.
000052 (2020) Yasuhiko Hirabayashi [Japon]Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
000055 (2020) Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]Tocilizumab treatment in COVID-19: A single center experience.
000061 (2020) Ver Nica Cantarín-Extremera [Espagne] ; María Jiménez-Legido [Espagne] ; Anna Duat-Rodríguez [Espagne] ; Marta García-Fernández [Espagne] ; Nelmar Valentina Ortiz-Cabrera [Espagne] ; María Luz Ruiz-Falc Rojas [Espagne] ; Luis González-Gutiérrez-Solana [Espagne]Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.
000063 (2020) Mitsuhiro Akiyama [Japon] ; Yuko Kaneko [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review.
000090 (2020) Muneyoshi Futami [Japon] ; Keisuke Suzuki [Japon] ; Satomi Kato [Japon] ; Saori Ohmae [Japon] ; Yoshio Tahara [Japon] ; Masanori Nojima [Japon] ; Yoichi Imai [Japon] ; Takayuki Mimura [Japon] ; Yoshihiro Watanabe [Japon] ; Arinobu Tojo [Japon]The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
000095 (2020) Chi Zhang [République populaire de Chine] ; Zhao Wu [République populaire de Chine] ; Jia-Wen Li [République populaire de Chine] ; Hong Zhao [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
000099 (2020) Carlo Perricone [Italie] ; Paola Triggianese [Italie] ; Elena Bartoloni [Italie] ; Giacomo Cafaro [Italie] ; Angelo F. Bonifacio [Italie] ; Roberto Bursi [Italie] ; Roberto Perricone [Italie] ; Roberto Gerli [Italie]The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
000118 (2020) Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000136 (2020) Gehan Elolemy [Koweït] ; Abdulrahman Al Rashidi [Koweït] ; Ahmed Dehrab [Koweït] ; Ammar Almathkouri [Koweït] ; Alex Varghese [Koweït] ; Mustafa Chikhly [Koweït] ; Fatema Alkhawaja [Koweït]Successful treatment of refractory lupus erythematosus profundus with the interleukin-6 antagonist tocilizumab: a case report.
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000159 (2020) Cem Gabay [Suisse] ; Gerd R. Burmester [Allemagne] ; Vibeke Strand [États-Unis] ; Jérôme Msihid [France] ; Moshe Zilberstein [États-Unis] ; Toshio Kimura [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Susan H. Boklage [États-Unis] ; Jonathan Sadeh [États-Unis] ; Neil M. H. Graham [États-Unis] ; Anita Boyapati [États-Unis]Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
000161 (2020) Shiyuan Wen [République populaire de Chine] ; Feng Wang [République populaire de Chine] ; Zhenhua Ji [République populaire de Chine] ; Yingyi Pan [République populaire de Chine] ; Miaomiao Jian [République populaire de Chine] ; Yunfeng Bi [République populaire de Chine] ; Guozhong Zhou [République populaire de Chine] ; Lisha Luo [République populaire de Chine] ; Taigui Chen [République populaire de Chine] ; Lianbao Li [République populaire de Chine] ; Zhe Ding [République populaire de Chine] ; Manzama-Esso Abi [République populaire de Chine] ; Aihua Liu [République populaire de Chine] ; Fukai Bao [République populaire de Chine]Salp15, a Multifunctional Protein From Tick Saliva With Potential Pharmaceutical Effects
000180 (2020) Emily Yi-Chih Ting ; Albert C. Yang [États-Unis] ; Shih-Jen Tsai [Taïwan]Role of Interleukin-6 in Depressive Disorder
000208 (2020) Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000256 (2020) Francesco Bennardo [Italie] ; Caterina Buffone [Italie] ; Amerigo Giudice [Italie]New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.
000279 (2020) Stefan Poschner ; Judith Wackerlig ; Dan Cacsire Castillo-Tong ; Andrea Wolf ; Isabel Von Der Decken ; Tea Lanišnik Rižner ; Renata Pavli ; Anastasia Meshcheryakova ; Diana Mechtcheriakova ; Monika Fritzer-Szekeres ; Theresia Thalhammer ; Walter J Ger [Autriche]Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "interleukin" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "interleukin" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    interleukin
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021